Management of Pediatric PTSD with SSRIs

Evidence for SSRIs in Pediatric PTSD

The American Academy of Child and Adolescent Psychiatry indicates that switching between SSRIs without a clear clinical indication is not supported by guidelines, as both medications are SSRIs with similar efficacy profiles 1
Guidelines suggest no significant differences in efficacy when switching from one SSRI to another in patients who have not yet failed initial treatment, according to the American College of Physicians 2, 3
Escitalopram and citalopram may have the least effect on cytochrome P450 enzymes compared to other SSRIs, potentially resulting in fewer drug-drug interactions, as noted by the American Academy of Child and Adolescent Psychiatry 1

Inadequate response after 8-12 weeks at therapeutic doses is a valid reason to consider switching, as recommended by the American Academy of Child and Adolescent Psychiatry 1
Intolerable side effects, such as gastrointestinal disturbances, sexual dysfunction, or activation, are also a reason to switch, according to the American Academy of Child and Adolescent Psychiatry 1
Discontinuation syndrome concerns, such as those associated with sertraline, should be considered when switching, as noted by the American Academy of Child and Adolescent Psychiatry 1
Drug-drug interactions, particularly with medications metabolized by CYP2D6, may make escitalopram a preferable option, as recommended by the American Academy of Child and Adolescent Psychiatry 1

All SSRIs carry a black box warning for increased suicidal thinking or behavior in children and adolescents, as required by the FDA and noted by the American Academy of Child and Adolescent Psychiatry 1
Paroxetine has been associated with increased risk of suicidal thinking compared to other SSRIs and should be avoided, according to the American Academy of Child and Adolescent Psychiatry 1
Conservative titration is recommended when dosing SSRIs in pediatric populations, with increases in smallest available increments at 1-2 week intervals, as recommended by the American Academy of Child and Adolescent Psychiatry 1

Optimizing the current SSRI dose before switching, ensuring adequate trial duration (8-12 weeks at therapeutic dose), is recommended by the American Academy of Child and Adolescent Psychiatry 1
Adding evidence-based psychotherapy, such as trauma-focused cognitive behavioral therapy (CBT), is a first-line approach for pediatric PTSD and should be combined with medication, as recommended by the American Academy of Child and Adolescent Psychiatry 1
Consideration of augmentation strategies should only occur after failed monotherapy trials, as noted by the American College of Physicians 3